Drug Approval | December 29, 2021
U.S. FDA approves Leo Pharma’s Adbry
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
It plans to deliver over 300 million doses to the Indian government
DCGI approved the drug based on the review of clinical data
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
Philips’s CavaClear is intended to safely ablate tissue to remove embedded IVC filters
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
The VaxIT app, developed on the Salesforce platform for Azim Premji Foundation and its partners, captures the status of vaccinations to help individuals plan and stay updated on their progress
2022 is going to be the year of opportunities and innovations from the medical industry in India
Subscribe To Our Newsletter & Stay Updated
